Palliative interventions and prognosis in patients with advanced esophageal cancer

Diseases of the Esophagus

Volumn 24, Issue 7, 2011, Pages 502-509

  Amdal, C D ^a   Jacobsen, A B ^a   Tausjo J E ^a   Wiig, J N ^b   Warloe, T ^b   Sandstad, B ^a   Bjordal, K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Esophageal cancer; Palliation; Retrospective study; Survival

Indexed keywords

ANALGESIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; OPIATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CAUSE OF DEATH; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; STENT; TREATMENT OUTCOME; TUMOR LOCALIZATION; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 80052977448     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01174.x     Document Type: Article

References (29)

1. Homs M Y, Kuipers E J, Siersema P D. Palliative therapy. J Surg Oncol 2005; 92: 246-56.
2. Valencia J J, Alonso O V, Esco B R, Lopez-Mata M, Mendez V A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 2006; 8: 22-30.
3. Fang F M, Tsai W L, Chiu H C, Kuo W R, Hsiung C Y. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 1394-404.
4. Calais G, Dorval E, Louisot P etal. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997; 38: 769-75.
5. Steyerberg E W, Homs M Y, Stokvis A, Essink-Bot M L, Siersema P D. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005; 62: 333-40.
6. Statistics Norway. Statbank. Norway. Cited 08.01.2011 Available from URL
7. Ogilvie A L, Dronfield M W, Ferguson R, Atkinson M. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 1982; 23: 1060-7.
8. Jacobs J P. Introduction - databases and the assessment of complications associated with the treatment of patients with congenital cardiac disease. Cardiol Young 2008; 18 (Suppl 2): 1-37.
9. Earlam R, Cunha-Melo J R. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 1980; 67: 381-90.
10. Lecleire S, Di Fiore F, Antonietti M etal. Undernutrition is predictive of early mortality after palliative self-expanding metal stent insertion in patients with inoperable or recurrent esophageal cancer. Gastrointest Endosc 2006; 64: 479-84.
11. Gaspar L E, Nag S, Herskovic A, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 1997; 38: 127-32.
12. Homs M Y, Steyerberg E W, Eijkenboom W M etal. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-504.
13. Madhusudhan C, Saluja S S, Pal S etal. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus 2009; 22: 331-6.
14. Sreedharan A, Harris K, Crellin A, Forman D, Everett S M. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 2009; 7 (4): CD005048.
15. Ilson D H, Saltz L, Enzinger P etal. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-5.
16. Ilson D H, Forastiere A, Arquette M etal. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-23.
17. TaxXel: Taxotere and Xeloda in Esophageal Cancer. A Phase I/II study on the treatment with taxotere in combination with xeloda in Patients with metastatic oesophageal cancer or cancer in the cardia region. [Cited 8 January 2011.] Available from URL:, ClinicalTrials.gov Identifier: NCT00821912.
18. Caspers R J, Welvaart K, Verkes R J, Hermans J, Leer J W. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol 1988; 12: 15-23.
19. Leslie M D, Dische S, Saunders M I etal. The role of radiotherapy in carcinoma of the thoracic oesophagus: an audit of the Mount Vernon experience 1980-1989. Clin Oncol (R Coll Radiol) 1992; 4: 114-8.
20. Sur R, Donde B, Falkson C etal. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy 2004; 3: 191-5.
21. Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia. Co-ordinated research project on improving outcomes in radiotherapy using new strategies of treatment delivery with focus on oesophageal cancer. [Cited 8 January 2011.] Available from URL:, ClinicalTrials.gov Identifier: NCT00665197.
22. Sur R K, Donde B, Levin V C, Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1998; 40: 447-53.
23. Homs M Y, Steyerberg E W, Eijkenboom W M, Siersema P D. Predictors of outcome of single-dose brachytherapy for the palliation of dysphagia from esophageal cancer. Brachytherapy 2006; 5: 41-8.
24. Javle M, Ailawadhi S, Yang G Y, Nwogu C E, Schiff M D, Nava H R. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol 2006; 4: 365-73, 379.
25. Bergquist H, Johnsson A, Hammerlid E, Wenger U, Lundell L, Ruth M. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther 2008; 27: 385-95.
26. McKernan M, McMillan D C, Anderson J R, Angerson W J, Stuart R C. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008; 98: 888-93.
27. Bergquist H, Wenger U, Johnsson E etal. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005; 18: 131-9.
28. Homs M Y, Essink-Bot M L, Borsboom G J, Steyerberg E W, Siersema P D. Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004; 40: 1862-71.
29. PACO: Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only. Palliation of dysphagia in patients with advanced cancer of the oesophagus by comparing stent followed by 3 courses of brachytherapy with 3 courses of brachytherapy only. A Randomised Phase III Study (PACO). [Cited 8 January 2011.] Available from URL:, ClinicalTrials.gov Identifier: NCT00653107, 2009.